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Introduction: Recent evidence suggests that tissue accumulation of senescent p16INK4a-positive cells during the life
span would be deleterious for tissue functions and could be the consequence of inherent age-associated disorders.
Osteoarthritis (OA) is characterized by the accumulation of chondrocytes expressing p16INK4a and markers of the
senescence-associated secretory phenotype (SASP), including the matrix remodeling metalloproteases MMP1/MMP13
and pro-inflammatory cytokines interleukin-8 (IL-8) and IL-6. Here, we evaluated the role of p16INK4a in the OA-induced
SASP and its regulation by microRNAs (miRs).
Methods: We used IL-1-beta-treated primary OA chondrocytes cultured in three-dimensional setting or mesenchymal
stem cells differentiated into chondrocyte to follow p16INK4a expression. By transient transfection experiments and the
use of knockout mice, we validate p16INK4a function in chondrocytes and its regulation by one miR identified by means
of a genome-wide miR-array analysis.
Results: p16INK4a is induced upon IL-1-beta treatment and also during in vitro chondrogenesis. In the mouse model, Ink4a
locus favors in vivo the proportion of terminally differentiated chondrocytes. When overexpressed in chondrocytes,
p16INK4a is sufficient to induce the production of the two matrix remodeling enzymes, MMP1 and MMP13, thus linking
senescence with OA pathogenesis and bone development. We identified miR-24 as a negative regulator of p16INK4a.
Accordingly, p16INK4a expression increased while miR-24 level was repressed upon IL-1-beta addition, in OA cartilage and
during in vitro terminal chondrogenesis.
Conclusions: We disclosed herein a new role of the senescence marker p16INK4a and its regulation by miR-24 during OA
and terminal chondrogenesis.Introduction
Tissue loss of function and integrity are inherent to aging
and age-related disease onset. Because senescent p16INK4a-
positive cells accumulate within numerous tissues through-
out life [1], recent strong evidence suggested that these cells
contribute to tissue degeneration by sustaining chronic in-
flammation and extracellular matrix remodeling [2]. In-
deed, p16INK4a-positive cells exhibit a specific secretome* Correspondence: jean-marc.brondello@inserm.fr
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including pro-inflammatory cytokines (such as interleukin-
6 (IL-6), IL-8, and IL-1β) and matrix remodeling regulatory
metalloproteases (such as MMP1 and MMP13) [2]. Re-
markably, specific conditional elimination of these cells in
a premature aging murine model has revealed their essen-
tial role in the onset of several age-related diseases [3].
Interestingly, Ink4a, which encodes an archetypical cyclin-
dependent inhibitor (CKI) associated with senescence, is
also known to participate in terminal differentiation onset
of several cellular lineages [4,5].
Osteoarthritis (OA) is a chronic degenerative disease
characterized by progressive cartilage erosion and lesionsl Ltd. This is an Open Access article distributed under the terms of the Creative
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The anabolic function of chondrocytes, the major cellular
component of articular cartilage, decreases with disease
progression. This loss of function is associated mainly with
an accumulation of p16INK4a-positive articular chondro-
cytes [7] harboring short telomeres [8] but also features of
hypertrophic/terminally differentiated cells [9,10]. The lat-
ter is normally associated with endochondral ossification
process during bone development [9,10]. Although OA
regulatory mechanisms remain under investigation, it's now
believed that articular mature chondrocytes in response to
either inflammatory cytokines or aberrant developmental
signals exemplified by Notch activation [10] are producing
matrix remodeling enzymes (MMP1 and MMP13) and in-
flammatory cytokines (IL-8 and IL-6) [11,12]. All of these
factors are deleterious for cartilage integrity. Therefore, OA
is a multi-factorial complex disease in which articular chon-
drocytes exhibit characteristics of senescent-like and
hypertrophic-like cells secreting SASP factors leading to
impaired anabolic capacities [7]. Moreover, a reduction of
p16INK4a expression by RNA interference in OA chondro-
cytes was shown to lead to their functional rescue [13].
These results demonstrate a deleterious role for this
senescence-associated CKI on articular chondrocytes. It re-
mains to be understood how p16INK4a increased expression
occurs and could contribute to OA progression.
MicroRNAs (miRs) are small non-coding RNAs that are
part of the miRNA-induced silencing complex (RISC) [14]
and are involved in the regulation of gene expression.
MiRs are key regulators of numerous physiological pro-
cesses that are deregulated in pathological conditions [15],
in particular OA [16,17]. Among miRs identified in OA,
miR-22 targets BMP7, a factor inducing chondrocyte ter-
minal differentiation [18]; miR-140 targets HDAC4, a
histone deacetylase inducer of chondrocyte terminal differ-
entiation [19,20]; and miR-27b targets MMP13, a key re-
modeling enzyme in hypertrophic terminally differentiated
chondrocyte [21]. So far, none of these miRs has been
found to be regulators of p16INK4a-associated senescent
phenotypes during OA progression.
In this study, we demonstrate that p16INK4a accumulates
not only in response to inflammatory stimuli but also dur-
ing chondrogenesis. Ink4a participates in cell cycle exit
required for chondrocyte terminal differentiation onset
during endochondral ossification. Moreover, p16INK4a
overexpression is sufficient to trigger MMP1 and MMP13
production in mature chondrocytes. By genome-wide
microRNA array, we identify miR-24 as a regulator of
p16INK4a in chondrocytes. As expected, miR-24 is re-
pressed in IL-1β-treated chondrocytes, in cartilages of pa-
tients with OA but also at the end of chondrogenesis
while p16INK4a accumulates. Finally, downregulation of
miR-24 by an antagomir approach in primary chondro-
cytes leads to an increase in p16INK4a expression andMMP1 secretion. Taken together, these data reveal for the
first time that the senescent marker p16INK4a and its epi-
genetic regulator miR-24 are reciprocally involved in both
OA and bone developmental-associated matrix remodel-
ing secretomes.
Materials and methods
Cell culture, chondrocytes, mesenchymal stem cells,
cartilage samples, and mouse models
Primary human chondrocytes were isolated from cartilage
of 11 OA patients (mean age of 62 years) undergoing knee
arthroplasty after informed written consent from patients
and approval by the local and national ethics committee
(‘Cellule de bioéthique de la direction générale pour la
recherche et innovation, Ministère de l’Enseignement
Supérieur et de la Recherche’; registration number DC-
2009-1052) were obtained, as described previously [22].
Cartilages from six healthy adult subjects (mean age of 53
years) were forensic waste from legal medicine with no
need of informed consent after consultation with the na-
tional ethics committee and in strict agreement with
French legislation. OA primary chondrocytes were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% fetal calf serum as described [23]. Primary
OA chondrocytes (2.5 × 105 cells) were pelleted by centrifu-
gation in 15-mL conical tubes, placed in three-dimensional
(3D) setting for 7 days in chondrogenic medium—DMEM
supplemented with 0.1 μM dexamethasone (Sigma-Aldrich,
St. Louis, MO, USA), 1 mM pyruvate sodium (Invitrogen,
Paisley, UK), 0.17 mM ascorbic acid (Sigma-Aldrich), 0.35
mM Proline (Sigma-Aldrich), 1% Insulin Transferin
Selenium (Lonza, Basel, Switzerland), 2 mM L-glutamine
(Lonza), 100 U/mL penicillin, and 100 μg/mL streptomycin
(Lonza)—supplemented with transforming growth factor-
beta 3 (TGF-β3) at 10 ng/mL (R&D Systems, Minneapolis,
MN, USA). Treatment with recombinant human IL-1β at
10 ng/mL (R&D Systems) was applied for the first 5 days.
Wild-type or ink4a knockout mice (1 month old) were
obtained as reported [24]. Mice were housed and cared for
in accordance with the laboratory animal care guidelines.
Approval was obtained from the regional ethics committee
on animal experimentation before initiation of the study
(approval CEEA-LR-10042). Experiments were performed
in accordance with the regional ethics committee on ani-
mal research and care.
MicroRNA array analysis
Total RNA was extracted from chondrocytes in micropel-
let treated (or not) with IL-1β by using a miRvana isolation
kit (Ambion, Carlsbad, CA, USA). MiRNA expression pro-
filing was performed by using Miltenyi (Bergisch Gladbach,
Germany) microarray facilities. Labeling and hybridization
were performed in accordance with the protocol of the
manufacturer. Raw data were normalized and additional
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Microarray data are available in the ArrayExpress database
[26] under accession number E-MTAB-2229.
Reverse transcription, microRNA reverse transcription,
and quantitative polymerase chain reaction
One microgram of Trizol-extracted total RNAs including
microRNAs from the different samples were poly(A)-
tailed with poly(A) polymerase (NEB M0276L). Then the
polyadenylated RNA samples were reverse-transcribed as
previously described using 50 units M-MLV Reverse Tran-
scriptase (Invitrogen, Carlsbad, CA, USA) and either ran-
dom primers or dTmiR adapter [27]. For microRNA and
mRNA quantitative analysis, cDNA was mixed with Sybr
Green Master Mix (Roche Diagnostics, Indianapolis, IN,
USA) in 96-well plates containing specific primers for hsa-
miR-24 (universal reverse + specific primer), interest genes
or the ribosomal subunit protein-9, housekeeping gene
(hRSP9). Quantitative polymerase chain reaction (qPCR)
conditions as described [27] used the following primer-
probe combinations: for hRSP9 sense 5′-GATTACATC
CTGGGCCTGAA antisense 5′-ATGAAGGACGGGAT
GTTCAC; for Aggrecan (hACAN) sense 5′- TCGAGGAC
AGCGAGGCC anti-sense 5′-TCGAGGGTGTAGCGTGT
AGAGA; for hCOL2A1, variant 2 (hCol2A1) sense 5′-CA
GACGCTGGTGCTGCT anti-sense 5′-TCCTGGTTGCC
GGA CAT; For hMMP13 sense 5′-TAAGGAGCATGGCG
ACTTCT anti-sense 5′-GTCTGGCGTTTTTGGATGTT;
for hp16INK4a sense 5′- GAAGGTCCCTCAGACATCCCC
anti-sense 5′-CCCTGTAGGACCTTCGGTGAC; for hsa-
miR-24 sense 5′-TGGCTCAGTTCAGCAGGAACAG Uni-
versal Reverse 5′- GCGAGCACAGAATTATACGACT.
cDNA constructs and luciferase reporter assay
Plasmids encoding for miR-24-2 promoter (−2041 base-
pair) Luciferase and CMV β-galactosidase were provided by
Charles Lecellier [28]. Empty vector or p16INK4a encoding
vector were purchased from Addgene [29]. For promoter
activity assay, OA human primary chondrocytes were
transfected at day 0, placed in pellet culture conditions
and treated with IL-1β during 48 hours. Cells were then
lysed according to the dual luciferase/βgal kit (Promega,
Charbonnières-les-Bains, France). Firefly Luciferase and
β-galactosidase activities were detected using specific
substrates with MultiScan FC (Thermo Scientific,
Loughborough, UK). Luciferase activity was normalized
to β-galactosidase activity.
In vitro differentiation of human bone marrow-
mesenchymal stromal cells to chondrocytes
Human bone marrow-mesenchymal stromal cell (hBM-
MSC) culture were established from bone marrow of pa-
tients undergoing Hip replacement surgery, after patient
informed written consent and approval by the local andnational ethics committee (“Cellule de bioéthique de la
direction générale pour la recherche et innovation, Minis-
tère de l’Enseignement supérieur et de la Recherche”;
registration number DC-2009-1052). Human mesenchy-
mal stromal cells (hMSCs) were isolated and amplified by
using a complete alpha-minimum essential medium sup-
plemented with 10% fetal bovine serum + 1 ng/mL of
basic fibroblast growth factor. hBM-MSCs were positive
for CD44, CD73, CD90, and CD105 but negative for
CD14, CD34, and CD45. Chondrogenic differentiation of
BM-MSCs was induced by 21-day culture in micropellet
[30]. Chondrogenesis was monitored by measuring the ex-
pression of chondrocyte-specific markers by reverse
transcription-qPCR (RT-qPCR) as described [30].
Transfections
Human chondrocytes (75 × 104) were transfected with 15
μg of plasmid for 24 hours by using Transit-LT1 Reagent
(Euromedex, Souffelweyersheim, France). Chondrocytes
were transfected with 100 nM of AntagomiR control or
AntagomiR-24 (purchased from Ambion) by using oligo-
fectamine (Invitrogen, USA). After transfection, cells were
trypsinized and pelleted in chondrogenic medium and cul-
tured for 7 days.
Western Blot and enzyme-linked immunosorbent assay
For Western blotting, chondrocytes in pellet cultures were
lysed in RIPA-Benzonase buffer [22]. After the addition of
the lysis buffer, the samples were left on ice for 15 minutes
with vortexing every 5 minutes for 10 seconds. Lysate pro-
tein samples were then sonicated for 5 minutes, followed
by centrifugation at 7000 g for 15 minutes. The protein
quantity loaded on Western blot gel corresponded to 25 ×
104 cells. Primary antibodies and dilutions were anti-
CDKN2A/p16INK4a (ab54210; Abcam; 1:1,000) and
anti-β actin (Sigma-Aldrich A228; 1:8,000). Secondary
antibody used for Western blot analysis was goat anti-
mouse IgG HRP conjugate (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA; 115-035-003;
1:80,000). Enzyme-linked immunosorbent assays (ELI-
SAs) were performed by using kits (IL-6, IL-8, pro-
MMP13, and MMP1) from R&D Systems on supernatants
stored at −20°C until analysis. Data were normalized and
expressed as picograms per milliliter.
Immunohistochemistry and staining
Samples were fixed in 3.7% paraformaldehyde for 24
hours, washed in phosphate-buffered saline (PBS), and
processed for routine histology. Paraffin-embedded sam-
ple sections (5 μm) were rehydrated through a gradient
of xylene and ethanol. Samples were first incubated for
20 minutes at room temperature with pepsin solution
(EmergoEurope, The Hague, The Netherlands) for anti-
gen retrieval. Endogenous peroxidase blocking was done
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ples were pre-incubated with blocking solution (PBS + 10%
goat serum + 0.1% Triton) for 30 minutes at room
temperature. Endogenous biotins were blocked by using a
Streptavidin/Biotin blocking kit (Vector SP-2002) for 30 mi-
nutes. Primary antibody anti-CDKN2A/p16INK4a monoclo-
nal mouse antibody (1:200; Abcam ab54210) was incubated
for 72 hours at 4°C. Incubation with Biotin-coupled second-
ary antibody, IgG (1:200; ABC kit Vector PK6100) was done
for 1 hour at room temperature. Incubation with Avidin/Bio-
tin complex (ABC kit Vector PK6100) was done for 30 mi-
nutes at room temperature. Immunolocalized antigens were
detected by means of a DAB revelation kit (Sigma-Aldrich).
Safranin-O staining was performed as described [31].
Quantification of proliferating cell nuclear antigen (PCNA)-
positive or PCNA-negative hypertrophic chondrocytes was
performed on four different sections of long bones of four
mice of each genotype by using ImageJ software (D-0426)
in accordance with the instructions of the manufacturer.
Statistical analysis
Experiments were performed with at least three independ-
ent individual chondrocyte or MSC samples. Comparisons
of two conditions were done by using a paired Student t
test. Unpaired Mann-Whitney test was applied for cartil-
age samples by using GraphPad Prism Software (Graph-
Pad Software, Inc., La Jolla, CA, USA). Differences were
considered significant when P values were less than 0.05.
Results and discussion
p16INK4a accumulates with other senescence-associated
secretory phenotype factors in interleukin-1-beta-treated
mature chondrocytes
We first wanted to establish an in vitro model based on
mature chondrocytes, mimicking the senescence-like phe-
notypes found in OA cartilage. This model should associ-
ate a 3D setting reproducing that of chondrocytes within
the tissue, expression of senescence markers such as
p16INK4a, and production of SASP factors. We therefore
isolated primary chondrocytes from OA cartilage patients
and that were placed in pellet culture conditions to main-
tain/reinduce the chondrocyte phenotype. We used IL-1β
as one of the major cytokine inducers of cartilage degrad-
ation in OA [32] to induce senescence-associated pheno-
type. We observed that, in response to chronic IL-1β
treatment for 5 days, mature chondrocytes lose (as ex-
pected) the expression of specific differentiation markers
such as Aggrecan (Figure 1A) [33], concomitantly with
p16INK4a accumulation (Figure 1B), phospho-active form of
p38MAPK (Figure 1C), and production of reactive oxygen
species (data not shown), hallmarks of senescence-
associated signaling pathways [34]. Furthermore, as ex-
pected, IL-1β-treated mature chondrocytes significantly
produce senescence-associated secretory factors such asMMP1 and MMP13, two markers normally associated
with chondrocyte terminal differentiation onset and IL-6
and IL-8, two pro-inflammatory cytokines (Figure 1D-G).
Therefore, this 3D in vitro model recapitulates the p16INK4a-
associated secretory phenotype characterizing senescent-like
chondrocytes found in OA cartilage.
The senescence marker p16INK4a is expressed during
in vitro chondrogenesis and participates in the terminal
differentiation-dependent cell cycle exit during
endochondral ossification
Besides inflammatory cytokines, aberrant chondrogenic dif-
ferentiation signals can also promote OA features. For in-
stance, Notch activation and HIF-2α transcription factor,
both inducers of OA, are also central in controlling chon-
drocyte terminal differentiation onset during in vitro chon-
drogenesis and in vivo endochondral ossification [9,10].
Thus, we next wanted to determine whether p16INK4a could
also be part of a normal in vitro and in vivo chondrogenic
differentiation process as has been reported for Notch or
HIF-2α. We therefore evaluated the p16INK4a expression
profile in human MSCs from three different donors under-
going TGF-β3-induced chondrogenic differentiation to re-
capitulate in vitro all stages of chondrogenesis. Surprisingly,
p16INK4a expression increases during chondrogenesis in
parallel with a chondrocyte differentiation marker such
as collagen IIB at days 7 to 14 and in a concomitant man-
ner with MMP13, a chondrocyte terminal differentiation
marker, at day 21 (Figure 2A-D). Of note, during chondro-
genesis, p14ARF mRNA, an alternative splicing form of
p16INK4a, was not detected at any time (data not shown).
Thus, the senescence marker p16INK4a, which is known to
be required for astrocyte [4] or epidermal cell [5] differenti-
ation, seems also to play a role during chondrogenesis. To
dissect its in vivo function during chondrogenic differenti-
ation, we compared the endochondral ossification process
of transgenic mice deficient in ink4a locus with that of wild-
type mice. PCNA and Safranin-O staining were used to
quantify proliferative chondrocytes versus non-proliferative
chondrocytes within the growth plate of 1-month-old mice.
Without affecting the total number of chondrocytes, ink4a
ablation reduces the height of hypertrophic terminally dif-
ferentiated non-proliferative chondrocytes by 48% ± 2.2
(Figure 2E-G), demonstrating a role for ink4a locus in
chondrocyte cell fate decision to engage in terminal differ-
entiation. A main function of p16INK4a is to specifically in-
hibit cell cycle progression by targeting G1 CDK4/6
activities [35] and therefore maintain retinoblastoma
(pRb), p107, and p130 under their active unphosphory-
lated forms [36]. These three pocket proteins are known
to control chondrocyte cell fate decision during bone
growth [37-39]. Interestingly, two other CKIs—p27KIP1
and p57KIP2—are also part of the cell cycle regulation
during terminal differentiation through CDK inhibition
Figure 1 Interleukin-1-beta (IL-1β) induces both p16INK4a expression and a senescence-associated secretory phenotype (SASP) in mature
chondrocytes. Osteoarthritis (OA) human primary chondrocytes were placed in pellet culture and treated with IL-1β (10 ng/mL) for 5 days. (A) Aggrecan
mRNA (Acan) expression level was evaluated by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) (n = 3). (B) p16INK4a
protein expression level was measured by Western blotting. (C) P-p38MAPK protein level was detected by immunohistochemistry (IHC) on a
section of paraffin-embedded pellets. Images were taken with a ×20 objective. (D-G) Matrix metalloprotease 1 (MMP1), MMP13, IL-6, and IL-8
secretion were measured by enzyme-linked immunosorbent assay (ELISA) (n = 4). Data are shown as mean ± standard deviation (SD) of fold
changes compared with control. *P <0.05, **P <0.01.
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p16INK4a plays a major role in both cellular senescence and
differentiation onset as revealed in ink4a knockout mice
studies. Taken together, these findings point at the multiple
roles of several CKIs and their indirect targets—pRb, p107,
and p130—as orchestrators of the differentiation program
and, in particular, in chondrocyte terminal differentiation
during bone development.
Expression of p16INK4a is sufficient for MMP1 and MMP13
secretion by mature chondrocytes
To determine how Ink4a could participate in both OA ini-
tiation and chondrocyte terminal differentiation, we
assessed whether p16INK4a expression impacts the estab-
lishment of matrix remodeling secretome common in
both events. We thus transiently transfected a p16INK4a-
encoding vector in human chondrocytes, before initiating
the pellet culture for 7 days and in the absence of IL-1β.
Overexpression of p16INK4a was checked at the mRNA
level (Figure 3A) and protein level (Figure 3B). Compared
with the control, p16INK4a-overexpressing mature chon-
drocytes produced significantly higher levels of MMP1
and MMP13 but did not modulate IL-6 and IL-8. Of note,
our findings confirm recent published data showing that
p16INK4a is dispensable for the establishment of inflamma-
tory secretome associated with senescent fibroblasts [42].Taken together, our results revealed that the senescence-
associated CKI, p16INK4a, triggers the secretion of both
MMP1 and MMP13 in mature chondrocytes. These two
metalloproteases are matrix remodeling enzyme family
members playing a central role in physiological and patho-
logical processes occurring in cartilage [33,43,44]. Indeed,
both are expressed during chondrocyte terminal differenti-
ation within the growth plate to coordinate matrix remod-
eling that promotes bone growth [12] but also in OA
articular cartilage during disease progression [45]. How
could p16INK4a control MMPs production? Firstly, ink4a
locus could directly regulate MMP1 transcriptional activa-
tion through its described physical interaction with APA1/
ZNF410 transcription factor which is bound to MMP1
promoter [46]. Secondly, by activating pRb-, p130-, and
p107-dependent terminal differentiation programs
through CDK inhibition, p16INK4a accumulation could also
contribute indirectly to MMPs production in OA and dur-
ing endochondral ossification. Indeed, these three
pocket proteins can modulate gene expression and cell
fate decision through their interactions with chromatin-
modifying enzymes [47]. One found, among these en-
zymes, histone deacetylase (HDAC) family members,
which are controlling chondrocyte pre-hypertrophy/hyper-
trophy transition [16,17]. Remarkably, recent work from
Culley and colleagues [48] reveals that pharmacological
Figure 2 MiR-24 and p16INK4a expressions during chondrogenesis and role of p16INK4a in chondrocyte cell cycle arrest. Human primary
mesenchymal stromal cells (MSCs) were placed in three-dimensional (3D) culture conditions for 21 days. RNAs were harvested at indicated time
points. (A-D) Gene expression analysis was performed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for Collagen
2b, matrix metalloprotease 13 (MMP13), p16INK4a, and miR-24. Data are shown as mean ± standard deviation (SD) (n = 3) normalized to D21.
Immunohistochemistry (IHC) was performed on sections of formalin fixed paraffin-embedded long bones of transgenic mice deficient in
p16INK4a or wild-type at the age of 1 month. (E,F) Growth plate was marked by Safranin-O staining and proliferating cell nuclear antigen
(PCNA) (P, proliferative zone; H, pre-hypertrophic/hypertrophic zone). Images were taken with ×20 objective. (G) Quantification of the
percentage of hypertrophic non-proliferative terminally differentiated cells on total cells within the growth plate in transgenic and wild-type mice
(n = 4) was carried out by using ImageJ software. Data were normalized to 1 for wild-type and are shown as mean ± SD. **P <0.01, ***P <0.001.
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proteases such as MMP13 by OA chondrocytes. Thus,
p16INK4a contributes to MMP secretion by activating
the pocket protein-HDAC axis in pathological and
physiological conditions.p16INK4a induction correlates with miR-24 repression in
interleukin-1-beta-treated chondrocytes, osteoarthritic
cartilage, and the end of an in vitro chondrogenesis
We next wanted to identify putative regulators of p16INK4a
in mature chondrocytes. Since miRs have been shown to
Figure 3 Cyclin-dependent kinase inhibitor p16INK4a participates in matrix metalloproteinase 1 (MMP1) and MMP13 expression in
mature chondrocytes. Osteoarthritis (OA) human primary chondrocytes were transfected with vector encoding for p16INK4a or empty vector (EV)
for 24 hours and placed in pellet for 7 days. (A) Gene expression analysis was performed by reverse transcription-quantitative polymerase chain
reaction (RT-qPCR) for p16INK4a (n = 5). (B) p16INK4a protein expression was detected by immunohistochemistry (IHC) on pellet paraffin sections.
Images were taken with a ×20 objective. (C-F) MMP1, MMP13, interleukin-6 (IL-6), and IL-8 secretions were measured by enzyme-linked immunosorbent
assay (ELISA) (n = 5). Data are shown as mean ± standard deviation (SD). *P <0.05.
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[16], we asked whether some miRs could regulate p16INK4a
expression in IL1β-treated chondrocytes. miR-array ana-
lysis was performed on small RNAs extracted from chon-
drocytes that were from three different donors and that
were cultured in pellets in the presence or absence of IL-
1β (Figure 4). Bioinformatic analysis revealed that 179miRs (128 up and 51 down) are differentially expressed in
response to IL-1β compared with untreated cells. These
deregulated miRs have at least a 1.4-fold change and a P
value of less than 0.05 (Figure 4A and data not shown).
Interestingly, we found among them several previously
OA-associated miRs such as miR-27b, miR-199, miR-29a,
miR-26, and miR-365 [16,17].
Figure 4 MiR-24 repression correlates with p16INK4a induction in interleukin-1-beta (IL-1β)-treated chondrocytes and osteoarthritis (OA)
cartilage. OA human primary chondrocytes are placed in pellet and treated with IL-1β at 10 ng/mL for 5 days. (A) List of microRNAs downregulated
by IL-1β. (B,C) Gene expression analysis was performed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for miR-24 and
p16INK4a (n = 3). (D) Luciferase/β-gal activities of promoter miR-24-2 cluster after IL-1β treatment (n = 3). Data are shown as mean ± standard deviation
(SD). MiR-24 repression in OA cartilage samples is shown. (E,F) MiR-24 repression in OA cartilage: gene expression for miR-24 and p16INK4a on OA
(n = 5) and healthy (n = 6) cartilage samples. *P <0.05, **P <0.01, ***P <0.001.
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Dicer induces senescence-associated phenotypes in pri-
mary cells [49] and promotes chondrocyte terminal differ-
entiation in animal models [50], we focused our attentionon miRs that were repressed by IL-1β (Figure 4A). We
found miR-24, a known negative regulator of p16INK4a,
through the presence of two binding sites for this miR
within its encoding and 3′ untranslated region (UTR) [51].
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samples placed in 3D, that IL-1β significantly repressed
miR-24 expression (Figure 4B) with a concomitant ex-
pected induction of p16INK4a mRNA (Figure 4C).
miR-24 is encoded by two genes: miR-24-1 and miR-24-2
[52]. These genes are organized in a cluster including three
different miRs (miR-23a or b/27a or b/24). Each cluster
is regulated by one promoter common for the three
miRs of the cluster [52]. Our array analysis revealed
that, upon IL-1β stimulation, chondrocytes show a re-
duced expression of several members of these two clus-
ters (Figure 4A), suggesting a global repression of the
transcription of the clusters. In keeping with this hy-
pothesis, we confirmed the transcriptional repression of
miR-24-2 promoter, upon IL-1β addition (Figure 4D),
by using a reporter luciferase assay (Figure 4D) previ-
ously described [28].
An increase in expression of p16INK4a has been demon-
strated in cartilage from patients with OA [13]. We then
checked whether miR-24 expression could be reversely
correlated with that of p16INK4a in OA cartilage compared
with healthy cartilage. By RT-qPCR on mRNA from OA
(n = 5) versus healthy (n = 6) human cartilage samples, we
revealed a significant miR-24 downregulation in OA cartil-
age (Figure 4E) while p16INK4a is increased (Figure 4F).
These results were confirmed at the protein level on
serial sections of OA cartilage samples by using
p16INK4a immunohistochemistry and miR-24 in situ
hybridization (Additional file 1).Figure 5 MiR-24 downregulation is sufficient to trigger p16INK4a expr
mature chondrocytes. Osteoarthritis (OA) human primary chondrocytes w
(A24) at a concentration of 100 nM. They were placed in pellet culture con
reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for
immunohistochemistry (IHC) on pellet paraffin-embedded sections. Images
and IL-8 secretion were measured by enzyme-linked immunosorbent assa
*P <0.05.Figure 2 shows that p16INK4a mRNA accumulates
throughout the time course of an in vitro chondrogenesis
from days 7 to 21 (Figure 2C). We therefore evaluated,
during chondrogenesis, whether the expression of miR-24
could also be reciprocal to that of p16INK4a expression. By
RT-qPCR, we revealed that, compared with days 0 to 7,
miR-24 level is decreased at day 14 and significantly at day
21 (Figure 2D) in parallel with an increase in expression of
the terminal differentiation marker, MMP13 (Figure 2B),
while p16INK4a remains elevated (Figure 2C). Taken to-
gether, these results demonstrate that the expressions of
Ink4a and its epigenetic regulator are mutually exclusive
in both in vitro and in vivo OA models and during the
end of the chondrogenesis. Moreover, miR-24 downregu-
lation seems to follow and sustain a high level of p16INK4a
rather than initiate p16INK4a accumulation.
MiR-24 downregulation is sufficient to trigger p16INK4a
expression and MMP1 production in mature chondrocytes
Finally, we aimed at determining whether modulation of
miR-24 could be sufficient to promote p16INK4a accumula-
tion and p16INK4a-dependent matrix remodeling secretome
by using our 3D chondrocyte model. Because miR-24 over-
expression has been reported to induce apoptosis by
repressing DNA damage response pathways [53], we relied
on a loss-of-function experiment based on transfection
of chondrocytes by either a specific inhibitor of miR-24
(antagomiR-24) or an irrelevant antagomiR as control. As
expected, transfection of antagomiR-24 led to a dramaticession and matrix metalloproteinase 1 (MMP1) production in
ere transfected with irrelevant antagomiR (Ctrl) and antagomiR-24
ditions for 7 days. (A,B) Gene expression analysis was performed by
miR-24 and p16INK4a (n = 4). (C) p16INK4a protein expression by
were taken with a ×20 objective. (D-G) MMP1, MMP13, interleukin-6 (IL-6),
y (ELISA) (n = 4). Data are shown as mean ± standard deviation (SD).
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comitant significant upregulation of p16INK4a at both
mRNA (Figure 5B) and protein levels as shown by im-
munostaining with p16INK4a antibodies (Figure 5C).
Furthermore, we showed that miR-24 downregulation is
sufficient to promote a marked increase in MMP1 secre-
tion (Figure 5D) but has no significant effect on MMP13,
IL-6, or IL-8 secretion (Figure 5E-G), suggesting the exist-
ence of a direct axis miR-24-p16INK4a-MMP1. The discrep-
ancy between this result and p16INK4a overexpression alone
could be explained by mutual redundancy and interference
between the signaling pathways. Nevertheless, miR-24 is
part of a cluster containing two other miRs and regulated
by the same promoter (Figure 4D). Therefore, miR-24 re-
pression is in vivo always accompanied by that of miR27a/b
and miR23a/b (Figure 4A and D). Remarkably, miR27b was
recently shown to inhibit MMP13 expression in IL-1β-
treated chondrocytes [21] and miR23a/b could negatively
regulate Runx2, a transcription factor involved in chondro-
cyte terminal differentiation, OA, and osteoblastogenesis
[54]. Thus, repression of these clusters during OA progres-
sion within articular cartilage would promote the appear-
ance of several OA-induced features, including p16INK4a,
MMP1, MMP13, but also Runx2. These findings propose
that miR-24-1/miR-24-2 clusters, together with the recently
identified miR-140, which targets ADAMTS5 and HDAC4,
two hypertrophic inducers [19,20], are crucial in preventing
chondrocyte terminal differentiation in OA.Conclusions
Determining the role and the regulatory pathways control-
ling p16INK4a expression in chondrocytes during OA pro-
gression is essential for future innovative long-term
therapeutic approaches. In the present work, we demon-
strated that the senescence CKI, p16INK4A, is also associ-
ated with chondrocyte terminal differentiation and can
regulate the expression of matrix remodeling metallopro-
teases MMP1 and MMP13. We further showed that miR-
24 expression plays a role as a negative regulator of the
p16INK4a/MMP1 axis.
We propose that—during OA progression, in response to
IL-1β, or during endochondral-induced terminal chondro-
genesis—a repression of miR-24- and miR-24-encoding
clusters takes place. This is likely to trigger p16INK4a,
MMP1, MMP13, and Runx2 expression, thereby pushing
chondrocytes toward a senescent-like phenotype resem-
bling that of terminally differentiated chondrocytes [7].
Accumulation of p16INK4a-positive chondrocytes within
articular cartilage could thus be deleterious not only for
tissue regeneration by blocking cell proliferation and re-
placement but also for tissue integrity through MMPs
secretion [7,55-57]. On the other hand, p16INK4a
accumulation within the growth plate will favor bonedevelopment. One therapeutic strategy for OA treat-
ment could be to restore/maintain the expression level
of miR-24-encoding clusters in order to prevent
p16INK4a-dependent pathways in articular chondrocytes.
Additional file
Additional file 1: p16INK4a and miR-24 are reversely correlated in
osteoarthritis (OA) articular cartilage. (A) p16INK4a immunohistochemistry
(IHC) on a cryosection of OA cartilage comprising superficial and
intermediate layer. (B) miR-24 in situ hybridization on an adjacent section of
the same OA cartilage sample. Results are representative of experiments on
two OA cartilage samples. Chondrocytes expressing either p16INK4a or
miR-24 are marked by arrows showing mutual exclusion. OA cartilage
samples were fixed with 4% paraformaldehyde during 3 hours at 4°C. After
fixation, samples were placed in PBS with sucrose 30% during 24 hours at
4°C. The next day, PBS-sucrose 30% was replaced with Tek OCT solution and
the samples were stored at −80°C. OA cartilage samples were sectioned at
13 μm and collected on Superfrost PLUS slides. In situ hybridization
experiment was performed as described [58]. LNA DIG-hsa-miR-24 probe
and DIG-has-miR-141c (as negative control) were purchased from Exiquon
(Copenhagen, Denmark) and diluted at 1pM. Alkaline phosphatase conjugated
anti-DIG- antibody was diluted at 1:2,000 in blocking solution. This file can be
viewed with Acrobat Reader.
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